Johnson & Johnson is a holding company engaged in the research and development, manufacture and sale of a range of products in the health care field. The company has three business segments: Consumer, which includes a range of products focused on personal healthcare used in the beauty, over-the-counter pharmaceutical, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension; and Medical Devices, which includes products used in the orthopaedic, surgery, interventional solutions, and eye health fields.
Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:
Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.
Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions.
Shift4 Payments, Inc. (FOUR) is simultaneously converting its existing clients to higher margin services while expanding its business into new verticals with large addressable markets in the payment processing market. Uniform Accounting confirms that the market isn't pricing this in. Considering management's strong execution and alignment to continue executing, equity upside is warranted Shift4 has been rapidly gaining market share in the payment processing industry with its gateway solutions for restaurants and lodging businesses, and it is converting its gateway clients into higher marg...
Johnson & Johnson (JNJ) currently trades below corporate but near historical averages relative to Uniform earnings, with a 16.3x Uniform P/E (Fwd. V/E'). At these levels, markets are pricing in expectations for Uniform ROA to compress from 25% in 2021 to 17% in 2026, accompanied by 3% Uniform asset growth. Meanwhile, analysts expect Uniform ROA to only fade to 22% in 2023, accompanied by 6% Uniform asset growth. If sustained going forward, these levels would imply a stock price closer to $275, representing significant potential equity upside for the firm. That said, the firm's most recent ...
Moody's Investors Service (Moody's) has assigned a definitive rating to the series A notes (the notes) co-issued by AASET 2022-1 Limited and AASET 2022-1 LLC (together, AASET 2022-1). AASET 2022-1 Limited is an exempted company incorporated with limited liability under the laws of the Cayman Islands...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.